Nuvalent (NASDAQ:NUVL) Reaches New 12-Month High – Should You Buy?

Nuvalent, Inc. (NASDAQ:NUVL) shares hit a new 52-week high during trading on Wednesday . The company traded as high as $123.83 and last traded at $123.77, with a volume of 1077919 shares traded. The stock had previously closed at $123.72.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. Cantor Fitzgerald lowered Nuvalent from an “overweight” rating to a “neutral” rating in a report on Tuesday, June 9th. Stifel Nicolaus set a $124.00 target price on Nuvalent in a report on Tuesday, June 9th. Wedbush downgraded shares of Nuvalent from an “outperform” rating to a “neutral” rating and cut their price target for the stock from $125.00 to $124.00 in a report on Tuesday, June 9th. Lifesci Capital lowered shares of Nuvalent from an “outperform” rating to a “hold” rating and set a $124.00 price target for the company. in a research report on Tuesday, June 9th. Finally, Robert W. Baird set a $122.85 price objective on shares of Nuvalent in a research note on Tuesday, June 9th. Four investment analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $127.73.

Nuvalent Stock Performance

The stock has a 50 day simple moving average of $110.40 and a two-hundred day simple moving average of $105.44. The firm has a market cap of $9.78 billion, a PE ratio of -20.42 and a beta of 1.14.

Nuvalent (NASDAQ:NUVL) last issued its earnings results on Thursday, May 7th. The company reported ($1.39) EPS for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.04). During the same period in the previous year, the firm posted ($1.18) earnings per share. Equities research analysts forecast that Nuvalent, Inc. will post -5.74 earnings per share for the current year.

Insider Activity

In related news, insider Henry E. Pelish sold 3,093 shares of the firm’s stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $104.48, for a total transaction of $323,156.64. Following the sale, the insider owned 65,604 shares in the company, valued at approximately $6,854,305.92. This trade represents a 4.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Alexandra Balcom sold 11,430 shares of Nuvalent stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $123.58, for a total value of $1,412,519.40. Following the completion of the transaction, the chief financial officer owned 85,533 shares of the company’s stock, valued at approximately $10,570,168.14. This represents a 11.79% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 96,953 shares of company stock valued at $9,709,133 in the last quarter. Company insiders own 5.02% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of NUVL. RA Capital Management L.P. purchased a new position in Nuvalent in the 3rd quarter valued at $107,794,000. Wellington Management Group LLP grew its holdings in shares of Nuvalent by 46.0% during the third quarter. Wellington Management Group LLP now owns 2,300,865 shares of the company’s stock worth $198,979,000 after buying an additional 724,491 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Nuvalent by 13.9% during the fourth quarter. Vanguard Group Inc. now owns 5,244,271 shares of the company’s stock worth $527,521,000 after buying an additional 639,264 shares in the last quarter. Norges Bank acquired a new stake in shares of Nuvalent in the fourth quarter valued at about $57,763,000. Finally, JPMorgan Chase & Co. raised its position in shares of Nuvalent by 32.9% in the fourth quarter. JPMorgan Chase & Co. now owns 2,205,251 shares of the company’s stock valued at $221,826,000 after buying an additional 545,542 shares during the last quarter. 97.26% of the stock is owned by hedge funds and other institutional investors.

About Nuvalent

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.